We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Avacta Sponsors 5th Annual Protein Formulation Development and Drug Delivery Forum

Read time: Less than a minute

Avacta Analytical has announced its sponsorship of this year’s Protein Formulation Development and Drug Delivery Forum in Barcelona, Spain.

Now in its fifth year, this exciting event runs from the 9th to the 11th of June, and will bring together research scientists from across the pharmaceutical and biotechnology sectors to explore current issues in protein formulation.

Protein formulation has become a highly important area of research for the pharmaceutical industry, and there is now increasing pressure to optimize drug formulations earlier in the development process to help avoid downstream failures and accelerate time-to-market.

This event will look at the latest innovations in protein formulation and drug delivery, highlighting recent research and technological advances - as well as updates to the regulatory framework - which can help to streamline and simplify formulation development activities.

Avacta will be showcasing the low volume protein characterization capabilities of the Optim 2 instrument at the event, giving delegates the opportunity to discuss how the system could help benefit their research with the Company’s technical experts.

Avacta’s Dr Geoff Platt will also be hosting a seminar entitled: ‘Strategy for stability assessment of antibodies: high throughput screening as a predictive tool for accelerating development’, providing practical examples of how novel technologies such as the Optim system can reduce the time and cost of therapeutic protein preformulation studies, protein stability testing and formulation development.